Search:
Formulary
New medicines
Shared care
Guidelines
Wound care
PGD
Self Care
Care Homes
>
6 Endocrine system
>
6.5 Hypothalamic and pituitary hormones and anti-oestrogens
>
6.5.2 Posterior pituitary hormones and antagonists
Homepage
Formulary Home
1 Gastro-intestinal system
1.1 Dyspepsia and gastro-oesophageal reflux disease
1.1.1 Antacids and simeticone
1.1.2 Compound alginates and proprietary indigestion preparations
1.2 Antispasmodics and other drugs altering gut motility
Eluxadoline for treating irritable bowel syndrome with diarrhoea - NICE TAG TA471
1.3 Antisecretory drugs and mucosal protectants
1.3.1 H2-receptor antagonists
1.3.2 Selective antimuscarinics
1.3.3 Chelates and complexes
1.3.4 Prostaglandin analogues
1.3.5 Proton pump inhibitors
1.4 Acute diarrhoea
1.4.1 Adsorbents and bulk-forming drugs
1.4.2 Antimotility drugs
1.4.3 Enkephalinase inhibitors
1.5 Chronic bowel disorders
1.5.1 Aminosalicylates
1.5.2 Corticosteroids
1.5.3 Drugs affecting the immune response
Ulcerative colitis (acute exacerbations) - infliximab - NICE TAG TA163
Crohn's disease - infliximab (review) and adalimumab (review of TA40) - NICE TAG TA187
Ulcerative colitis (subacute manifestations) - infliximab - NICE TAG TA140
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) - NICE TAG TA329
Vedolizumab for treating moderately to severely active ulcerative colitis - NICE TAG TA342
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy - NICE TAG TA352
Tofacitinib for moderately to severely active ulcerative colitis - NICE TAG TA547
1.5.4 Food allergy
1.6 Laxatives
1.6.1 Bulk-forming laxatives
1.6.2 Stimulant laxatives
1.6.3 Faecal softeners
1.6.4 Osmotic laxatives
1.6.5 Bowel cleansing preparations
1.6.6 Peripheral opioid-receptor antagonists
Naloxegol for treating opioid‑induced constipation - NICE TAG TA345
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) - NICE TAG TA468
1.6.7 Other drugs used in constipation
Constipation (women) - prucalopride - NICE TAG TA211
Lubiprostone for treating chronic idiopathic constipation - NICE TAG TA318
1.7 Local preparations for anal and rectal disorders
1.7.1 Soothing haemorrhoidal preparations
1.7.2 Compound haemorrhoidal preparations with corticosteroids
1.7.3 Rectal sclerosants
1.7.4 Management of anal fissures
1.8 Stoma care
1.9 Drugs affecting intestinal secretions
1.9.1 Drugs affecting biliary composition and flow
1.9.2 Bile acid sequestrants
Obeticholic acid for treating primary biliary cholangitis - NICE TAG TA443
1.9.3 Aprotinin
1.9.4 Pancreatin
2 Cardiovascular system
2.1 Positive inotropic drugs
2.1.1 Cardiac glycosides
2.1.2 Phosphodiesterase type-3 inhibitors
2.2 Diuretics
2.2.1 Thiazides and related diuretics
2.2.2 Loop diuretics
2.2.3 Potassium-sparing diuretics and aldosterone antagonists
2.2.4 Potassium-sparing diuretics with other diuretics
2.2.5 Osmotic diuretics
2.3 Anti-arrhythmic drugs
2.3.1 Management of arrhythmias
2.3.2 Drugs for arrhythmias
Dronedarone for the treatment of non-permanent atrial fibrillation - NICE TAG TA197
2.4 Beta-adrenoceptor blocking drugs
2.5 Hypertension and heart failure
2.5.1 Vasodilator antihypertensive drugs
2.5.2 Centrally acting antihypertensive drugs
2.5.3 Adrenergic neurone blocking drugs
2.5.4 Alpha-adrenoceptor blocking drugs
2.5.5 Drugs affecting the renin-angiotensin system
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction - NICE TAG TA388
2.6 Nitrates, calcium-channel blockers, and other antianginal drugs
2.6.1 Nitrates
2.6.2 Calcium-channel blockers
2.6.3 Other antianginal drugs
Chronic heart failure – ivabradine - NICE TAG TA267
2.6.4 Peripheral vasodilators and related drugs
Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate - NICE TAG TA223
2.7 Sympathomimetics
2.7.1 Inotropic sympathomimetics
2.7.2 Vasoconstrictor sympathomimetics
2.7.3 Cardiopulmonary resuscitation
2.8 Anticoagulants and protamine
2.8.1 Parenteral anticoagulants
Myocardial infarction (persistent ST-segment elevation) - bivalirudin - NICE TAG TA230
2.8.2 Oral anticoagulants
Atrial fibrillation - dabigatran etexilate - NICE TAG TA249
Atrial fibrillation (stroke prevention) - rivaroxaban - NICE TAG TA256
Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban - NICE TAG TA287
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban - NICE TAG TA275
Venous thromboembolism - dabigatran - NICE TAG TA157
Venous thromboembolism (hip and knee surgery) - apixaban - NICE TAG TA245
Venous thromboembolism - rivaroxaban - NICE TAG TA170
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban - NICE TAG TA261
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism - NICE TAG TA327
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome - NICE TAG TA335
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism - NICE TAG TA341
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation - NICE TAG TA355
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism - NICE TAG TA354
2.8.3 Protamine sulfate
2.9 Antiplatelet drugs
Acute coronary syndrome - prasugrel - NICE TAG TA182
Vascular disease - clopidogrel and dipyridamole - NICE TAG TA210
Acute coronary syndromes - ticagrelor - NICE TAG TA236
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) - NICE TAG TA317
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) - NICE TAG TA351
Ticagrelor for preventing atherothrombotic events after myocardial infarction - NICE TAG TA420
2.10 Stable angina, acute coronary syndromes, and fibrinolysis
2.10.1 Management of stable angina and acute coronary syndromes
2.10.2 Fibrinolytic drugs
Myocardial infarction - thrombolysis - NICE TAG TA52
Stroke (acute, ischaemic) - alteplase - NICE TAG TA264
2.11 Antifibrinolytic drugs and haemostatics
2.12 Lipid-regulating drugs
Cardiovascular disease - statins - NICE TAG TA94
Hypercholesterolaemia - ezetimibe - NICE TAG TA132
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia - NICE TAG TA385
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia - NICE TAG TA385
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia - NICE TAG TA394
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia - NICE TAG TA393
2.13 Local sclerosants
2.14 Other cardiovascular drugs
3 Respiratory system
3.1 Bronchodilators
3.1.1 Adrenoceptor agonists
3.1.2 Antimuscarinic bronchodilators
3.1.3 Theophylline
3.1.4 Compound bronchodilator preparations
3.1.5 Peak flow meters, inhaler devices and nebulisers
3.2 Corticosteroids
Asthma (in children) - corticosteroids - NICE TAG TA131
Asthma (in adults) - corticosteroids - NICE TAG TA138
3.3 Cromoglicate and related therapy, leukotriene receptor antagonists, and phosphodiesterase type-4 inhibitors
3.3.1 Cromoglicate and related therapy
3.3.2 Leukotriene receptor antagonists
3.3.3 Phosphodiesterase type-4 inhibitors
Roflumilast for treating chronic obstructive pulmonary disease - NICE TAG TA461
3.4 Antihistamines, hyposensitisation, and allergic emergencies
3.4.1 Antihistamines
3.4.2 Allergen immunotherapy
Venom anaphylaxis - immunotherapy pharmalgen - NICE TAG TA246
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) - NICE TAG TA278
Omalizumab for previously treated chronic spontaneous urticaria - NICE TAG TA339
Mepolizumab for treating severe refractory eosinophilic asthma - NICE TAG TA431
Reslizumab for treating severe eosinophilic asthma - NICE TAG TA479
Benralizumab for treating severe eosinophilic asthma - NICE TAG TA565
3.4.3 Allergic emergencies
3.5 Respiratory stimulants and pulmonary surfactants
3.5.1 Respiratory stimulants
3.5.2 Pulmonary surfactants
3.6 Oxygen
3.7 Mucolytics
Cystic fibrosis - mannitol dry powder for inhalation - NICE TAG TA266
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation - NICE TAG TA398
3.8 Aromatic inhalations
3.9 Cough preparations
3.9.1 Cough suppressants
3.9.2 Demulcent and expectorant cough preparations
3.10 Systemic nasal decongestants
3.11 Antifibrotics
Idiopathic pulmonary fibrosis - pirfenidone - NICE TAG TA282
Pirfenidone for treating idiopathic pulmonary fibrosis - NICE TAG TA504
3.12 Miscellaneous
4 Central nervous system
4.1 Hypnotics and anxiolytics
4.1.1 Hypnotics
Insomnia - newer hypnotic drugs - NICE TAG TA77
4.1.2 Anxiolytics
4.1.3 Barbiturates
4.2 Drugs used in psychoses and related disorders
4.2.1 Antipsychotic drugs
Schizophrenia - aripiprazole - NICE TAG TA213
Bipolar disorder (children) - aripiprazole - NICE TAG TA292
4.2.2 Antipsychotic depot injections
4.2.3 Drugs used for mania and hypomania
4.3 Antidepressant drugs
4.3.1 Tricyclic and related antidepressant drugs
4.3.2 Monoamine-oxidase inhibitors
4.3.3 Selective serotonin re-uptake inhibitors (SSRIs)
4.3.4 Other antidepressant drugs
Vortioxetine for treating major depressive episodes - NICE TAG TA367
4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) - NICE TAG TA98
4.5 Drugs used in the treatment of obesity
4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract
4.5.2 Centrally acting appetite suppressants
4.6 Drugs used in nausea and vertigo
4.7 Analgesics
4.7.1 Non-opioid analgesics and compound analgesic preparations
4.7.2 Opioid analgesics
4.7.3 Neuropathic pain
4.7.4 Antimigraine drugs
Migraine (chronic) - botulinum toxin type A - NICE TAG TA260
4.8 Antiepileptic drugs
4.8.1 Control of the epilepsies
Epilepsy (partial) - retigabine (adjuvant) - NICE TAG TA232
4.8.2 Drugs used in status epilepticus
4.8.3 Febrile convulsions
4.9 Drugs used in parkinsonism and related disorders
4.9.1 Dopaminergic drugs used in Parkinson's disease
4.9.2 Antimuscarinic drugs used in parkinsonism
4.9.3 Drugs used in essential tremor, chorea, tics, and related disorders
Motor neurone disease - Riluzole - Nice TAG TA20
4.10 Drugs used in substance dependence
4.10.1 Alcohol dependence
Nalmefene for reducing alcohol consumption in people with alcohol dependence - NICE TAG TA325
4.10.2 Nicotine dependence
Smoking cessation - varenicline - NICE TAG TA123
4.10.3 Opioid dependence
Drug misuse - methadone and buprenorphine - NICE TAG TA114
Drug misuse - naltrexone - NICE TAG TA115
Naltrexone–bupropion for managing overweight and obesity - NICE TAG TA494
4.11 Drugs for dementia
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease - NICE TAG TA217
5 Infections
5.1 Antibacterial drugs
5.1.1 Penicillins
5.1.2 Cephalosporins, carbapenems, and other beta-lactams
5.1.3 Tetracyclines
5.1.4 Aminoglycosides
5.1.5 Macrolides
5.1.6 Clindamycin
5.1.7 Some other antibacterials
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin - NICE TAG TA276
Rifaximin for preventing episodes of overt hepatic encephalopathy - NICE TAG TA337
5.1.8 Sulfonamides and trimethoprim
5.1.9 Antituberculosis drugs
5.1.10 Antileprotic drugs
5.1.11 Metronidazole and tinidazole
5.1.12 Quinolones
5.1.13 Urinary-tract infections
5.2 Antifungal drugs
5.2.1 Triazole antifungals
5.2.2 Imidazole antifungals
5.2.3 Polyene antifungals
5.2.4 Echinocandin antifungals
5.2.5 Other antifungals
5.3 Antiviral drugs
5.3.1 HIV infection
5.3.2 Herpesvirus infections
5.3.2.2 Cytomegalovirus infection
5.3.3 Viral hepatitis
5.3.3.1 Chronic hepatitis B
Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a - NICE TAG TA96
Hepatitis B - entecavir - NICE TAG TA153
Hepatitis B - telbivudine - NICE TAG TA154
Hepatitis B - tenofovir disoproxil fumarate - NiCE TAG TA173
5.3.3.2 Chronic hepatitis C
Hepatitis C - peginterferon alfa and ribavirin - NICE TAG TA200
Hepatitis C (genotype 1) - telaprevir - NICE TAG TA252
Hepatitis C (genotype 1) - boceprevir - NICE TAG TA253
Glecaprevir–pibrentasvir for treating chronic hepatitis C - NICE TAG TA499
Hepatitis C (children and young people) - peginterferon alfa and ribavirin NICE TAG TA300
Sofosbuvir for treating chronic hepatitis C - NICE TAG TA330
Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis - NICE TAG TA331
Ledipasvir–sofosbuvir for treating chronic hepatitis C - NICE TAG TA363
Daclatasvir for treating chronic hepatitis C - NICE TAG TA364
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C - NICE TAG TA365
Elbasvir–grazoprevir for treating chronic hepatitis C - NICE TAG TA413
Sofosbuvir–velpatasvir for treating chronic hepatitis C - NICE TAG TA430
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C - NICE TAG TA507
5.3.4 Influenza
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir - NICE TAG TA158
Influenza - zanamivir, amantadine and oseltamivir (review) - NICE TAG (TA168)
5.3.5 Respiratory syncytial virus
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C - NICE TAG TA75
5.4 Antiprotozoal drugs
5.4.1 Antimalarials
5.4.2 Amoebicides
5.4.3 Trichomonacides
5.4.4 Antigiardial drugs
5.4.5 Leishmaniacides
5.4.6 Trypanocides
5.4.7 Drugs for toxoplasmosis
5.4.8 Drugs for pneumocystis pneumonia
5.5 Anthelmintics
5.5.1 Drugs for threadworms
5.5.2 Ascaricides
5.5.3 Drugs for tapeworm infections
5.5.4 Drugs for hookworms
5.5.5 Schistosomicides
5.5.6 Filaricides
5.5.7 Drugs for cutaneous larva migrans
5.5.8 Drugs for strongyloidiasis
6 Endocrine system
6.1 Drugs used in diabetes
6.1.1 Insulins
6.1.2 Antidiabetic drugs
Type 2 diabetes in adults: management - NICE NG28
Dapagliflozin in combination therapy for treating type 2 diabetes - NICE TAG TA288
Canagliflozin in combination therapy for treating type 2 diabetes - NICE TAG TA315
Empagliflozin in combination therapy for treating type 2 diabetes - NICE TAG TA336
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes - NICE TAG TA390
Dapagliflozin in triple therapy for treating type 2 diabetes - NICE TAG TA418
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes - NICE TAG TA572
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes - NICE TAG TA583
6.1.3 Diabetic ketoacidosis
6.1.4 Treatment of hypoglycaemia
6.1.5 Treatment of diabetic nephropathy and neuropathy
6.1.6 Diagnostic and monitoring devices for diabetes mellitus
6.2 Thyroid and antithyroid drugs
6.2.1 Thyroid hormones
6.2.2 Antithyroid drugs
6.3 Corticosteroids
6.3.1 Replacement therapy
6.3.2 Glucocorticoid therapy
6.4 Sex hormones
6.4.1 Female sex hormones and their modulators
6.4.2 Male sex hormones and antagonists
6.4.3 Anabolic steroids
6.5 Hypothalamic and pituitary hormones and anti-oestrogens
6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens
Growth hormone deficiency (adults) - human growth hormone - NICE TAG TA64
Human growth hormone (somatropin) for the treatment of growth failure in children (review) - NICE TAG TA188
6.5.2 Posterior pituitary hormones and antagonists
Tolvaptan for treating autosomal dominant polycystic kidney disease - NICE TAG 358
6.6 Drugs affecting bone metabolism
6.6.1 Calcitonin and parathyroid hormone
6.6.2 Bisphosphonates and other drugs affecting bone metabolism
Osteoporosis - primary prevention - NICE TAG TA160
Osteoporosis - secondary prevention including strontium ranelate - NICE TAG TA161
Osteoporotic fractures - denosumab - NICE TAG TA204
Bone metastases from solid tumours – denosumab - NICE TAG TA265
Bisphosphonates for treating osteoporosis - NICE TAG TA464
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) - NICE TAG TA549
6.7 Other endocrine drugs
6.7.1 Bromocriptine and other dopaminergic drugs
6.7.2 Drugs affecting gonadotrophins
6.7.3 Metyrapone
6.7.4 Somatomedins
7 Obstetrics, gynaecology, and urinary-tract disorders
7.1 Drugs used in obstetrics
7.1.1 Prostaglandins and oxytocics
7.1.2 Mifepristone
7.1.3 Myometrial relaxants
7.2 Treatment of vaginal and vulval conditions
7.2.1 Preparations for vaginal and vulval changes
7.2.2 Vaginal and vulval infections
7.3 Contraceptives
7.3.1 Combined hormonal contraceptives
7.3.2 Progestogen-only contraceptives
7.3.3 Spermicidal contraceptives
7.3.4 Contraceptive devices
7.3.5 Emergency contraception
7.4 Drugs for genito-urinary disorders
7.4.1 Drugs for urinary retention
7.4.2 Drugs for urinary frequency, enuresis, and incontinence
Overactive bladder - mirabegron - NICE TAG TA290
7.4.3 Drugs used in urological pain
7.4.4 Bladder instillations and urological surgery
7.4.5 Drugs for erectile dysfunction
7.4.6 Drugs for premature ejaculation
8 Malignant disease and immunosuppression
8.1 Cytotoxic drugs
8.1.1 Alkylating drugs
Leukaemia (lymphocytic) - bendamustine - NICE TAG TA216
8.1.2 Anthracyclines and other cytotoxic antibiotics
Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) - NICE TAG TA91
Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy NICE TAG TA306
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia - NICE TAG 552
8.1.3 Antimetabolites
Pancreatic cancer - gemcitabine - Nice TAG TA25
Leukaemia (lymphocytic) - fludarabine - NICE TAG TA29
Colorectal cancer - capecitabine and tegafur uracil - NICE TAG TA61
Renal transplantation - immuno-suppressive regimens (adults) - NICE TAG TA85
Colon cancer (adjuvant) - capecitabine and oxaliplatin - NICE TAG TA100
Breast cancer - gemcitabine - NICE TAG TA116
Leukaemia (lymphocytic) - fludarabine - NICE TAG TA119
Lung cancer (non-small-cell) - pemetrexed - NICE TAG TA124
Mesothelioma - pemetrexed disodium NICE TAG TA135
Lung cancer (non-small-cell, first line treatment) - pemetrexed - NICE TAG TA181
Lung cancer (non-small-cell) - pemetrexed (maintenance) - NICE TAG TA190
Gastric cancer (advanced) - capecitabine - NICE TAG TA191
Myelodysplastic syndromes - azacitidine - NICE TAG TA218
Lung cancer (non small cell, non squamous) - pemetrexed NICE TAG TA309
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin - NICE TAG TA402
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts - NICE TAG TA399
Cladribine tablets for treating relapsing–remitting multiple sclerosis - NICE TAG TA493
Decitabine for untreated acute myeloid leukaemia (terminated appraisal) - NICE TAG TA548
8.1.4 Vinca alkaloids and etoposide
Urothelial tract carcinoma (transitional cell, advanced, metastatic) – vinflunine - NICE TAG TA272
8.1.5 Other antineoplastic drugs
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) - NICE TAG TA23
Breast cancer - trastuzumab - NICE TAG TA34
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block- NICE TAG TA55
Gastrointestinal stromal tumours - imatinib - NICE TAG TA86
Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) - NICE TAG TA91
Prostate cancer (hormone-refractory) - docetaxel - NICE TAG TA101
Breast cancer (early) - trastuzumab - NICE TAG TA107
Breast cancer (early) - paclitaxel - NICE TAG TA108
Breast cancer (early) - docetaxel - NICE TAG TA109
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer- NICE TAG TA118
Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide - NICE TAG TA121
Multiple myeloma - bortezomib - NICE TAG TA129
Head and neck cancer - cetuximab - NICE TAG TA145
Lung cancer (non-small-cell) - erlotinib - NICE TAG TA162
Renal cell carcinoma - sunitinib - NICE TAG TA169
Head and neck cancer (squamous cell carcinoma) - cetuximab - NICE TAG TA172
Colorectal cancer (first line) - cetuximab - NICE TAG TA176
Renal cell carcinoma - NICE TAG TA178
Gastrointestinal stromal tumours - sunitinib - NICE TAG TA179
Cervical cancer (recurrent) - topotecan - NICE TAG TA183
Lung cancer (small-cell) - topotecan - NICE TAG TA184
Soft tissue sarcoma - trabectedin - NICE TAG TA185
Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) - NICE TAG TA189
Lung cancer (non-small-cell, first line) - gefitinib - NICE TAG TA192
Gastrointestinal stromal tumours - imatinib (adjuvant) - NICE TAG TA196
Gastric cancer (HER2-positive metastatic) - trastuzumab - NICE TAG TA208
Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib - NICE TAG TA209
Colorectal cancer (metastatic) - bevacizumab - NICE TAG TA212
Breast cancer - bevacizumab (in combination with a taxane) - NICE TAG TA214
Pazopanib for the first-line treatment of advanced renal cell carcinoma - NICE TAG TA215
Everolimus for the second-line treatment of advanced renal cell carcinoma - NICE TAG TA219
Ovarian cancer (relapsed) - trabectedin - NIE TAG TA222
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) - NICE TAG TA227
Multiple myeloma (first line) - bortezomib and thalidomide - NICE TAG TA228
Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) - NICE TAG TA241
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab - NICE TAG TA242
Breast cancer (advanced) - eribulin - NICE TAG TA250
Leukaemia (chronic myeloid, first line) - dasatanib, nilotinib and standard-dose imatinib - NICE TAG TA251
Prostate cancer - cabazitazel - NICE TAG TA255
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) - NICE TAG TA257
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) - NICE TAG TA258
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer - NICE TAG TA263
Melanoma (stage III or IV) - ipilimumab - NICE TAG TA268
Melanoma (BRAF V600 mutation positive, unresectable metastatic) – vemurafenib - NICE TAG TA269
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer - NICE TAG TA284
Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab - NICE TAG TA285
Myelofibrosis (splenomegaly, symptoms) - ruxolitinib - NICE TAG TA289
Guidance on the use of imatinib for chronic myeloid leukaemia - NICE TAG TA70
Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) - NICE TAG TA295
Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib NICE TAG TA296
Leukaemia (chronic myeloid) - bosutinib NICE TAG TA299
Macular oedema (central retinal vein occlusion) - aflibercept solution for injection NICE TAG TA305
Colorectal cancer (metastatic) - aflibercept NICE TAG TA307
Lung cancer (non small cell, EGFR mutation positive) - afatinib NICE TAG TA310
Multiple myeloma - bortezomib (induction therapy) NICE TAG TA311
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma - NICE TAG TA319
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma - NICE TAG TA321
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196) - NICE TAG TA326
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment - NICE TAG TA333
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG TA357
Ruxolitinib for treating polycythaemia vera (terminated appraisal) - NICE TAG 356
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) - NICE TAG TA353
Aflibercept for treating diabetic macular oedema - NICE TAG TA346
Everolimus for preventing organ rejection in liver transplantation - NICE TAG TA348
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer - NICE TAG TA347
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) - NICE TAG TA334
Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) - NICE TAG TA328
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG 357
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) - NICE TAG TA362
Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer - NICE TAG TA360
Idelalisib for treating chronic lymphocytic leukaemia - NICE TAG TA359
Pembrolizumab for advanced melanoma not previously treated with ipilimumab - NICE TAG TA366
Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane - NICE TAG TA371
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy - NICE TAG TA374
Bortezomib for previously untreated mantle cell lymphoma - NICE TAG TA370
Nintedanib for treating idiopathic pulmonary fibrosis - NICE TAG TA379
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy - NICE TAG TA378
Panobinostat for treating multiple myeloma after at least 2 previous treatments - NICE TAG TA380
Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy - NICE TAG TA381
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis - NICE TAG TA386
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer - NICE TAG TA389
Nivolumab for treating advanced (unresectable or metastatic) melanoma - NICE TAG TA384
Bosutinib for previously treated chronic myeloid leukaemia - NICE TAG TA401
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer - NICE TAG TA403
Nivolumab in combination with ipilimumab for treating advanced melanoma - NICE TAG TA400
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma - NICE TAG TA396
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel - NICE TAG TA391
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer - NICE TAG TA395
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA406
Pegaspargase for treating acute lymphoblastic leukaemia - NICE TAG TA408
Talimogene laherparepvec for treating unresectable metastatic melanoma - NICE TAG TA410
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer - NICE TAG TA411
Trifluridine–tipiracil for previously treated metastatic colorectal cancer - NICE TAG TA405
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma - NICE TAG TA414
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer - NICE TAG TA416
Nivolumab for previously treated advanced renal cell carcinoma - NICE TAG TA417
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy - NICE TAG TA421
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA422
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens - NICE TAG TA423
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer - NICE TAG TA424
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia - NICE TAG TA425
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia - NICE TAG TA426
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy- NICE TAG TA428
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer - NICE TAG TA439
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation - NICE TAG TA429
Everolimus for advanced renal cell carcinoma after previous treatment - NICE TAG TA432
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA462
Carfilzomib for previously treated multiple myeloma - NICE TAG TA457
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane - NICE TAG TA458
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) - NICE TAG TA452
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) - NICE TAG TA453
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) - NICE TAG TA453
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma - NICE TAG TA446
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer - NICE TAG TA447
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease - NICE TAG TA449
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia - NICE TAG451
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) - NICE TAG TA444
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA540
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine - NICE TAG TA535
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) - NICE TAG TA469
Cabozantinib for previously treated advanced renal cell carcinoma - NICE TAG TA463
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer - NICE TAG TA476
Sorafenib for treating advanced hepatocellular carcinoma - NICE TAG TA474
Ibrutinib for treating Waldenstrom’s macroglobulinaemia - NICE TAG TA491
Vismodegib for treating basal cell carcinoma - NICE TAG TA489
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours - NICE TAG TA488
Venetoclax for treating chronic lymphocytic leukaemia - NICE TAG TA487
Ibrutinib for treating relapsed or refractory mantle cell lymphoma - NICE TAG TA502
Ceritinib for untreated ALK-positive non-small-cell lung cancer - NICE TAG TA500
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma - NICE TAG TA498
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma - NICE TAG TA505
Cabozantinib for treating medullary thyroid cancer - NICE TAG TA516
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen - NICE TAG TA515
Regorafenib for previously treated advanced hepatocellular carcinoma - NICE TAG TA514
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma - NICE TAG TA510
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer - NICE TAG TA509
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NICE TAG TA519
Avelumab for treating metastatic Merkel cell carcinoma - NICE TAG TA517
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy - NICE TAG TA520
Arsenic trioxide for treating acute promyelocytic leukaemia - NICE TAG TA526
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NICE TAG TA525
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma - NICE TAG TA524
Midostaurin for untreated acute myeloid leukaemia - NICE TAG TA523
Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable - NICE TAG TA522
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer - NICE TAG TA531
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy - NICE TAG TA530
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer - NICE TAG TA529
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer - NIE TAG TA528
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours - NICE TAG TA539
Dinutuximab beta for treating neuroblastoma - NICE TAG TA538
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer - NICE TAG TA536
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine - NICE TAG TA535
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia - NICE TAG TA541
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA540
Cabozantinib for untreated advanced renal cell carcinoma - NICE TAG TA542
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma - NICE TAG TA544
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia - NICE TAG TA545
Vandetanib for treating medullary thyroid cancer - NICE TAG TA550
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer - NICE TAG TA557
Regorafenib for previously treated advanced hepatocellular carcinoma - NICE TAG TA555
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence - NICE TAG TA553
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years - NICE TAG TA554
Lenvatinib for untreated advanced hepatocellular carcinoma - NICE TAG TA551
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) - NICE TAG TA560
Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) - NICE TAG TA 564
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA563
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma - NICE TAG TA562
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia - NICE TAG TA561
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) - NICE TAG TA560
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib - NICE TAG TA571
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) - NICE TAG TA570
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer - NICE TAG TA569
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies - NICE TAG TA567
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies - NICE TA TAG567
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma - NICE TAG TA577
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) - NICE TAG TA576
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma - NICE TAG TA573
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) - NICE TAG TA582
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma - NICE TAG TA581
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy - NICE TAG TA579
Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation - NICE TAG TA578
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer - NICE TAG TA584
8.2 Drugs affecting the immune response
8.2.1 Antiproliferative immunosuppressants
Renal transplantation - immunosuppressive regimens for children and adolescents - NICE TAG TA99
8.2.2 Corticosteroids and other immunosuppressants
Renal transplantation - immuno-suppressive regimens (adults) - NICE TAG TA85
Renal transplantation - immunosuppressive regimens for children and adolescents - NICE TAG TA99
Daclizumab for treating relapsing–remitting multiple sclerosis - NICE TAG TA441
Immunosuppressive therapy for kidney transplant in children and young people - NICE TAG TA482
Immunosuppressive therapy for kidney transplant in adults - NICE TAG TA481
Ocrelizumab for treating relapsing–remitting multiple sclerosis - NICE TAG TA533
Ocrelizumab for treating primary progressive multiple sclerosis - NICE TAG TA585
8.2.3 Anti-lymphocyte monoclonal antibodies
Non-Hodgkin's lymphoma - rituximab - NICE TAG TA65
Lymphoma (follicular non-Hodgkin's) - rituximab NICE TAG TA137
Leukaemia (chronic lymphocytic, first line) - rituximab - NICE TAG TA174
Leukaemia (chronic lymphocytic, relapsed) - rituximab - NICE TAG TA193
Chronic lymphocytic leukaemia - ofatumumab - NICE TAG TA202
Lymphoma (follicular non-Hodgkin's) - rituximab - NICE TAG TA226
Follicular lymphoma - rituximab - NICE TAG TA243
Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) NICE TAG TA308
Multiple sclerosis (relapsing-remitting) - alemtuzumab NICE TAG TA312
Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia - NICE TAG TA344
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia - NICE TAG TA343
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia - TA450
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck - NICE TAG TA473
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab - NICE TAG TA472
Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) - NICE TAG TA470
Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma - NICE TAG TA465
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma - NIE TAG TA478
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable - NICE TAG TA492
Obinutuzumab for untreated advanced follicular lymphoma - NICE TAG TA513
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity - NICE TAG TA589
8.2.4 Other immunomodulating drugs
Multiple sclerosis - beta interferon and glatiramer acetate - NICE TAG TA32
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases - NICE TAG TA412
Hepatitis C - pegylated interferons, ribavirin and alfa interferon - NICE TAG TA75
Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a - NICE TAG TA96
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C - NICE TAG TA106
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases - NICE TAG TA376
Multiple sclerosis - natalizumab - NICE TAG TA127
Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy - NICE TAG TA171
Multiple myeloma (first line) - bortezomib and thalidomide - NICE TAG TA228
Osteosarcoma - mifamurtide - NICE TAG TA235
Multiple sclerosis (relapsing-remitting) - fingolimod - NICE TAG TA254
Multiple sclerosis (relapsing) - teriflunomide NICE TAG TA303
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis - NICE TAG TA320
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality - NICE TAG TA322
Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib - NICE TAG TA338
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib - NICE TAG TA427
Dimethyl fumarate for treating moderate to severe plaque psoriasis - TAG TA475
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy - NICE TAG TA490
Nivolumab for previously treated non-squamous non-small-cell lung cancer - NICE TAG TA484
Nivolumab for previously treated squamous non-small-cell lung cancer - NICE TAG TA483
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA462
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer - NICE TAG TA501
Tivozanib for treating advanced renal cell carcinoma - NICE TAG TA512
Beta interferons and glatiramer acetate for treating multiple sclerosis - NICE TAG TA527
Padeliporfin for untreated localised prostate cancer - NICE TAG TA546
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease - NICE TAG TA558
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies - NICE TAG TA559
Lenalidomide plus dexamethasone for previously untreated multiple myeloma - NICE TAG TA587
8.3 Sex hormones and hormone antagonists in malignant disease
8.3.1 Oestrogens
8.3.2 Progestogens
8.3.3 Androgens
8.3.4 Hormone antagonists
8.3.4.1 Breast Cancer
Breast cancer (early) - hormonal treatments - NICE TAG TA112
Breast cancer (metastatic) - fulvestrant - NICE TAG TA239
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer - NICE TAG TA503
8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen- NICE TAG TA259
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen - NICE TAG TA316
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - NICE TAG TA377
Degarelix for treating advanced hormone-dependent prostate cancer - NICE TAG TA404
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - NICE TAG TA387
Enzalutamide for hormone-relapsed non-metastatic prostate cancer - NICE TAG TA580
8.3.4.3 Somatostatin analogues
9 Nutrition and blood
9.1 Anaemias and some other blood disorders
9.1.1 Iron-deficiency anaemias
9.1.2 Drugs used in megaloblastic anaemias
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias
Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin -NICE TAG TA142
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142) - NICE TAG TA323
9.1.4 Drugs used in platelet disorders
Thrombocytopenic purpura - eltrombopag - NICE TAG TA205
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura - NICE TAG TA221
Thrombocytopenic purpura - eltrombopag - NICE TAG TA293
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) - NICE TAG TA382
9.1.5 G6PD deficiency
9.1.6 Drugs used in neutropenia
9.1.7 Drugs used to mobilise stem cells
9.2 Fluids and electrolytes
9.2.1 Oral preparations for fluid and electrolyte imbalance
9.2.2 Parenteral preparations for fluid and electrolyte imbalance
9.3 Intravenous nutrition
9.4 Oral nutrition
9.4.1 Foods for special diets
9.4.2 Enteral nutrition
9.5 Minerals
9.5.1 Calcium and magnesium
Hyperparathyroidism - cinacalcet - NICE TAG TA117
Etelcalcetide for treating secondary hyperparathyroidism - NICE TAG TA448
9.5.2 Phosphorus
9.5.3 Fluoride
9.5.4 Zinc
9.5.5 Selenium
9.6 Vitamins
9.6.1 Vitamin A
9.6.2 Vitamin B group
9.6.3 Vitamin C
9.6.4 Vitamin D
9.6.5 Vitamin E
9.6.6 Vitamin K
9.6.7 Multivitamin preparations
9.7 Bitters and tonics
9.8 Metabolic disorders
9.8.1 Drugs used in metabolic disorders
9.8.2 Acute porphyrias
10 Musculoskeletal and joint diseases
10.1 Drugs used in rheumatic diseases and gout
10.1.1 Non-steroidal anti-inflammatory drugs
10.1.2 Corticosteroids
10.1.3 Drugs that suppress the rheumatic disease process
Arthritis (juvenile idiopathic) - etanercept - NICE TAG TA35
Rheumatoid arthritis - adalimumab, etanercept and infliximab - NICE TAG TA130
Ankylosing spondylitis - adalimumab, etanercept and infliximab- NICE TAG TA143
Rheumatoid arthritis - certolizumab pegol - NICE TAG TA186
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor - NICE TAG TA195
Psoriatic arthritis - etanercept, infliximab and adalimumab - NICE TAG TA199
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs - NICE TAG445
Psoriatic arthritis - golimumab - NICE TAG TA220
Rheumatoid arthritis (after failure of previous anti-rheumatic drugs) - golimumab - NICE TAG TA225
Ankylosing spondylitis - golimumab - NICE TAG TA233
Arthritis (juvenile idiopathic, systemic) - tocilizumab - NICE TAG TA238
Rheumatoid arthritis - tocilizumab - NICE TAG TA247
Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234) - NICE TAG TA280
Psoriatic arthritis (active) - ustekinumab NICE TAG TA313
Apremilast for treating active psoriatic arthritis - NICE TAG TA372
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis - NICE TAG TA373
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed - NICE TAG TA375
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis - NICE TAG TA 383
Belimumab for treating active autoantibody-positive systemic lupus erythematosus - NICE TAG TA397
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors - NICE TAG TA407
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor - NICE TAG TA415
Apremilast for treating active psoriatic arthritis - NICE TAG TA433
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment - NICE TAG TA456
Baricitinib for moderate to severe rheumatoid arthritis - NICE TAG TA466
Tofacitinib for moderate to severe rheumatoid arthritis - NICE TAG TA480
Sarilumab for moderate to severe rheumatoid arthritis - NICE TAG TA485
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA496
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA495
Golimumab for treating non-radiographic axial spondyloarthritis - NICE TAG TA497
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee - NICE TAG TA508
Tocilizumab for treating giant cell arteritis - NICE TAG TA518
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs - NICE TAG TA543
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) - NICE TAG TA568
Tildrakizumab for treating moderate to severe plaque psoriasis - NICE TAG TA575
Certolizumab pegol for treating moderate to severe plaque psoriasis - NICE TAG TA574
10.1.4 Gout and cytotoxic-induced hyperuricaemia
Hyperuricaemia - febuxostat - NICE TAG TA164
Gout (tophaceous, severe debilitating, chronic) - pegloticase - NICE TAG TA291
Lesinurad for treating chronic hyperuricaemia in people with gout - NICE TAG TA506
10.1.5 Other drugs for rheumatic diseases
10.2 Drugs used in neuromuscular disorders
10.2.1 Drugs that enhance neuromuscular transmission
10.2.2 Skeletal muscle relaxants
10.3 Drugs for the treatment of soft-tissue disorders and topical pain relief
10.3.1 Enzymes
Collagenase clostridium histolyticum for treating Dupuytren's contracture - NICE TAG TA459
10.3.2 Rubefacients, topical NSAIDs, capsaicin, and poultices
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee - NICE TAG TA477
11 Eye
11.1 Administration of drugs to the eye
11.2 Control of microbial contamination
11.3 Anti-infective eye preparations
11.3.1 Antibacterials
11.3.2 Antifungals
11.3.3 Antivirals
11.4 Corticosteroids and other anti-inflammatory preparations
11.4.1 Corticosteroids
Macular oedema (retinal vein occlusion) - dexamethasone - NICE TAG TA229
Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) NICE TAG TA301
Dexamethasone intravitreal implant for treating diabetic macular oedema - NICE TAG TA349
Cenegermin for treating neurotrophic keratitis - NICE TAG TA532
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis - NICE TAG TA590
11.4.2 Other anti-inflammatory preparations
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears - NICE TAG TA369
Adalimumab and dexamethasone for treating non-infectious uveitis - NICE TAG TA460
11.5 Mydriatics and cycloplegics
11.6 Treatment of glaucoma
11.7 Local anaesthetics
11.8 Miscellaneous ophthalmic preparations
11.8.1 Tear deficiency, ocular lubricants, and astringents
11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment
Macular degeneration (age-related) - photodynamic therapy - NICE TAG TA68
Holoclar for treating limbal stem cell deficiency after eye burns - NICE TAG TA467
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration - NICE TAG TA155
Aflibercept for treating choroidal neovascularisation - NICE TAG TA486
Macular oedema (diabetic) - ranibizumab - NICE TAG TA274
Macular oedema (retinal vein occlusion) - ranibizumab - NICE TAG TA283
Macular degeneration (wet age-related) - aflibercept (1st line) - NICE TAG TA294
Vitreomacular traction - ocriplasmin NICE TAG TA297
Choroidal neovascularisation (pathological myopia) - ranibizumab NICE TAG TA298
Macular oedema (central retinal vein occlusion) - aflibercept solution for injection NICE TAG TA305
Colorectal cancer (metastatic) - aflibercept NICE TAG TA307
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion - NICE TAG TA409
11.9 Contact lenses
12 Ear, nose, and oropharynx
12.1 Drugs acting on the ear
12.1.1 Otitis externa
12.1.2 Otitis media
12.1.3 Removal of ear wax
Cochlear implants for children and adults with severe to profound deafness - NICE TAG TA566
12.2 Drugs acting on the nose
12.2.1 Drugs used in nasal allergy
12.2.2 Topical nasal decongestants
12.2.3 Nasal preparations for infection
12.3 Drugs acting on the oropharynx
12.3.1 Drugs for oral ulceration and inflammation
12.3.2 Oropharyngeal anti-infective drugs
12.3.3 Lozenges and sprays
12.3.4 Mouthwashes, gargles, and dentifrices
12.3.5 Treatment of dry mouth
13 Skin
13.1 Management of skin conditions
13.1.1 Vehicles
13.1.2 Suitable quantities for prescribing
13.1.3 Excipients and sensitisation
13.2 Emollient and barrier preparations
13.2.1 Emollients
13.2.2 Barrier preparations
13.3 Topical local anaesthetics and antipruritics
13.4 Topical corticosteroids
Atopic dermatitis (eczema) - topical steroids - NICE TAG TA81
13.5 Preparations for eczema and psoriasis
13.5.1 Preparations for eczema
Eczema (chronic) - alitretinoin - NICE TAG TA177
13.5.2 Preparations for psoriasis
13.5.3 Drugs affecting the immune response
Atopic dermatitis (eczema) - pimecrolimus and tacrolimus - NICE TAG TA82
Psoriasis - efalizumab and etanercept - NICE TAG TA103
Psoriasis - infliximab - NICE TAG TA134
Psoriasis - adalimumab - NICE TAG TA146
Psoriasis - ustekinumab - NICE TAG TA180
Psoriatic arthritis - etanercept, infliximab and adalimumab - NICE TAG TA199
Psoriatic arthritis (active) - ustekinumab NICE TAG TA313
Ustekinumab for treating active psoriatic arthritis - NICE TAG TA340
Adalimumab for treating moderate to severe hidradenitis suppurativa - NICE TAG TA392
Secukinumab for treating moderate to severe plaque psoriasis - NICE TAG TA350
Apremilast for treating moderate to severe plaque psoriasis- NICE TAG TA419
Ixekizumab for treating moderate to severe plaque psoriasis - NICE TAG TA442
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people - NICE TAG TA455
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment - NICE TAG TA456
Brodalumab for treating moderate to severe plaque psoriasis - NICE TAG TA511
Guselkumab for treating moderate to severe plaque psoriasis - NICE TAG TA521
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs - NICE TAG TA537
Dupilumab for treating moderate to severe atopic dermatitis - NICE TAG TA534
13.6 Acne and rosacea
13.6.1 Topical preparations for acne
13.6.2 Oral preparations for acne
13.7 Preparations for warts and calluses
13.8 Sunscreens and camouflagers
13.8.1 Sunscreen preparations
13.8.2 Camouflagers
13.9 Shampoos and other preparations for scalp and hair conditions
13.10 Anti-infective skin preparations
13.10.1 Antibacterial preparations
13.10.2 Antifungal preparations
13.10.3 Antiviral preparations
13.10.4 Parasiticidal preparations
13.10.5 Preparations for minor cuts and abrasions
13.11 Skin cleansers, antiseptics, and desloughing agents
13.11.1 Alcohols and saline
13.11.2 Chlorhexidine salts
13.11.3 Cationic surfactants and soaps
13.11.4 Iodine
13.11.5 Phenolics
13.11.6 Oxidisers and dyes
13.11.7 Desloughing agents
13.12 Antiperspirants
13.13 Topical circulatory preparations
14 Immunological products and vaccines
14.1 Active immunity
14.2 Passive immunity
14.3 Storage and use
14.4 Vaccines and antisera
14.5 Immunoglobulins
14.5.1 Normal immunoglobulin
14.5.2 Disease-specific immunoglobulins
14.5.3 Anti-D (Rh0) immunoglobulin
Pregnancy (rhesus negative women) - routine anti-D (review) - NICE TAG TA156
14.6 International travel
15 Anaesthesia
15.1 General anaesthesia
15.1.1 Intravenous anaesthetics
15.1.2 Inhalational anaesthetics
15.1.3 Antimuscarinic drugs
15.1.4 Sedative and analgesic peri-operative drugs
15.1.5 Neuromuscular blocking drugs
15.1.6 Drugs for reversal of neuromuscular blockade
15.1.7 Antagonists for central and respiratory depression
15.1.8 Drugs for malignant hyperthermia
15.2 Local anaesthesia
Miscellaneous
New medicines / ACE
Guidelines
1. Gastro-intestinal System
2. Cardiovascular System Guidelines
3. Respiratory System Guidelines
4. Central Nervous System Guidelines
5. Infections Guidelines
6. Endocrine System Guidelines
7. Obstetrics, Gynaecology, and Urinary-tract Disorders Guidelines
8. Malignant Disease and Immunosuppression Guidelines
9. Nutrition and Blood Guidelines
10. Musculoskeletal and Joint Diseases Guidelines
11. Eye Guidelines
12. Ear, Nose, and Oropharynx Guidelines
13. Skin Guidelines
14. Immunological Products and Vaccines Guidelines
15. Anaesthesia Guidelines
Shared care
1. Gastro-intestinal System Shared Care
2. Cardiovascular System Shared Care
3. Respiratory System Shared Care
4. Central Nervous System Shared Care
5. Infections Shared Care
6. Endocrine System Shared Care
7. Obstetrics, Gynaecology, and Urinary-tract Disorders Shared Care
8. Malignant Disease and Immunosuppression Shared Care
9. Nutrition and Blood Shared Care
10. Musculoskeletal and Joint Diseases Shared Care
11. Eye Shared Care
12. Ear, Nose, and Oropharynx Shared Care
13. Skin Shared Care
14. Immunological Products and Vaccines Shared Care
15. Anaesthesia Shared Care
Wound care
Patient Group Directions (PGDs)
PGDs for hepatitis A and typhoid vaccines
FAQs
Further information
Newsletters
Referral forms
Self Care
Care Homes
High Cost Drugs
MTRAC
COVID-19
6.5.2 Posterior pituitary hormones and antagonists
Tolvaptan for treating autosomal dominant polycystic kidney disease - NICE TAG 358
Site by
Devopa
© Copyright 2024 NHS. All rights reserved.